# Customer Discovery: AgentGuard

**Specific Pain**
"We want to let our autonomous agents take real actions and spend money, but we can't because we have no way to prove to compliance that they won't hallucinate, leak data, or blow our budget."

**Early Adopter Profile**
The Head of AI Engineering or VP of Engineering at a Series B+ fintech, healthcare, or enterprise SaaS company. They have a working prototype of an agentic workflow that creates massive value, but Infosec or Compliance is actively blocking them from putting it into production because of risk.

**5 Discovery Questions**
1. Walk me through the last time you tried to push an autonomous agent workflow to production and were stopped—what exactly happened and who made the call?
2. How are you currently tracking the cost and decision-making steps of your multi-step LLM processes today?
3. When your compliance or security team asks you "how do you know the agent won't access restricted data," what is your answer right now?
4. Can you show me the custom code or workarounds you've built internally to try and add guardrails or human-in-the-loop pauses to your agents?
5. How much time does your engineering team spend writing custom routing logic and state management for your agent workflows?

**Validation Criteria**
- They bring up compliance, Infosec, or budget unpredictability without you prompting them.
- They have already built a messy, brittle internal solution (like nested `if/else` statements or hardcoded prompt filters) to solve this.
- They have a specific, high-value use case currently blocked from production solely due to governance concerns.

**Vitamin or Painkiller Verdict**
Currently, a **Vitamin** for most, but a **Painkiller** for the specific early adopter profile. For the average company building toy bots, this is a vitamin—nice to have but not urgent. For a company in a regulated industry trying to automate a core workflow, the lack of governance is a hard blocker. If they can't solve this, they can't launch. You must only talk to the latter.